AR024998A1 - Nuevos retinoides para el tratamiento del enfisema - Google Patents

Nuevos retinoides para el tratamiento del enfisema

Info

Publication number
AR024998A1
AR024998A1 ARP000103950A ARP000103950A AR024998A1 AR 024998 A1 AR024998 A1 AR 024998A1 AR P000103950 A ARP000103950 A AR P000103950A AR P000103950 A ARP000103950 A AR P000103950A AR 024998 A1 AR024998 A1 AR 024998A1
Authority
AR
Argentina
Prior art keywords
disease
treatment
new
new retinoids
retinoids
Prior art date
Application number
ARP000103950A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR024998A1 publication Critical patent/AR024998A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16Unsaturated compounds
    • C07C61/28Unsaturated compounds polycyclic
    • C07C61/29Unsaturated compounds polycyclic having a carboxyl group bound to a condensed ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66Polycyclic acids with unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP000103950A 1999-08-02 2000-07-31 Nuevos retinoides para el tratamiento del enfisema AR024998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115223 1999-08-02

Publications (1)

Publication Number Publication Date
AR024998A1 true AR024998A1 (es) 2002-11-06

Family

ID=8238709

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103950A AR024998A1 (es) 1999-08-02 2000-07-31 Nuevos retinoides para el tratamiento del enfisema

Country Status (18)

Country Link
US (3) US6528677B1 (enExample)
EP (1) EP1206436B1 (enExample)
JP (1) JP3961827B2 (enExample)
KR (1) KR100466730B1 (enExample)
CN (1) CN1166618C (enExample)
AR (1) AR024998A1 (enExample)
AT (1) ATE279386T1 (enExample)
AU (1) AU772551B2 (enExample)
BR (1) BR0012951A (enExample)
CA (1) CA2386793C (enExample)
DE (1) DE60014928T2 (enExample)
DK (1) DK1206436T3 (enExample)
ES (1) ES2228587T3 (enExample)
MX (1) MXPA02000828A (enExample)
PT (1) PT1206436E (enExample)
TR (1) TR200200263T2 (enExample)
WO (1) WO2001009076A2 (enExample)
ZA (1) ZA200200516B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US7914437B2 (en) * 2005-02-04 2011-03-29 Ams Research Corporation Transobturator methods for installing sling to treat incontinence, and related devices
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
HRP20160430T1 (hr) 2007-09-10 2016-05-20 Boston Biomedical, Inc. Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma
US9730909B2 (en) 2010-03-19 2017-08-15 Boston Biomedical, Inc Methods for targeting cancer stem cells
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
EP2768307B1 (en) * 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
RS59007B1 (sr) 2014-02-03 2019-08-30 Vitae Pharmaceuticals Llc Dihidropirolopiridinski inhibitori ror-gama
EA031967B1 (ru) 2014-10-14 2019-03-29 Вайтаи Фармасьютиклз, Инк. ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ROR-γ調節劑
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87821A1 (fr) * 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

Also Published As

Publication number Publication date
BR0012951A (pt) 2002-04-30
DE60014928T2 (de) 2006-03-09
KR20020030089A (ko) 2002-04-22
KR100466730B1 (ko) 2005-01-24
CN1166618C (zh) 2004-09-15
PT1206436E (pt) 2004-12-31
EP1206436B1 (en) 2004-10-13
WO2001009076A2 (en) 2001-02-08
US20030176726A1 (en) 2003-09-18
MXPA02000828A (es) 2002-07-30
AU6437300A (en) 2001-02-19
US6528677B1 (en) 2003-03-04
US6828337B2 (en) 2004-12-07
DK1206436T3 (da) 2005-02-14
EP1206436A2 (en) 2002-05-22
CA2386793A1 (en) 2001-02-08
JP3961827B2 (ja) 2007-08-22
CA2386793C (en) 2006-03-28
JP2003526626A (ja) 2003-09-09
TR200200263T2 (tr) 2004-12-21
CN1368946A (zh) 2002-09-11
ES2228587T3 (es) 2005-04-16
US20050113447A1 (en) 2005-05-26
DE60014928D1 (de) 2004-11-18
WO2001009076A3 (en) 2001-07-19
ZA200200516B (en) 2003-06-25
ATE279386T1 (de) 2004-10-15
AU772551B2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
AR029174A1 (es) Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
AR044923A1 (es) Imidazoquinolinas sustituidas con sulfonamida
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
MX9203444A (es) Medicamentos.
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
CR7510A (es) DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
AR025351A1 (es) Agonistas retinoides selectivos par
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
MX9300399A (es) Derivados heterotriciclicos.
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
UY27034A1 (es) Derivados de pirimidina
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
UY27324A1 (es) Nuevas sales de napsilato i
AR050260A1 (es) Derivados de diarilmetilpiperazinas, su preparacion y su utilizacion
AR013241A1 (es) Derivados del acido aminoetilfenoxiacetico, composicion farmaceutica que incluye a dicho derivado, medicamento para reducir el dolor y promover la eliminacion de calculos en urolitiasis, utilizacion de dicho derivado para la fabricacion de dicha composicion farmaceutica y procedimiento para la fabri
AR026451A1 (es) Compuestos heterociclicos sililados

Legal Events

Date Code Title Description
FB Suspension of granting procedure